rs387906281
Positions:
Variant summary
Our verdict is Pathogenic. Variant got 14 ACMG points: 14P and 0B. PVS1_StrongPM2PP5_Very_Strong
The NM_033087.4(ALG2):βc.1040delGβ(p.Gly347fs) variant causes a frameshift change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.0000552 in 1,611,228 control chromosomes in the GnomAD database, with no homozygous occurrence. Variant has been reported in ClinVar as Likely pathogenic (β β ).
Frequency
Genomes: π 0.000072 ( 0 hom., cov: 33)
Exomes π: 0.000053 ( 0 hom. )
Consequence
ALG2
NM_033087.4 frameshift
NM_033087.4 frameshift
Scores
Not classified
Clinical Significance
Conservation
PhyloP100: 7.50
Genes affected
ALG2 (HGNC:23159): (ALG2 alpha-1,3/1,6-mannosyltransferase) This gene encodes a member of the glycosyltransferase 1 family. The encoded protein acts as an alpha 1,3 mannosyltransferase, mannosylating Man(2)GlcNAc(2)-dolichol diphosphate and Man(1)GlcNAc(2)-dolichol diphosphate to form Man(3)GlcNAc(2)-dolichol diphosphate. Defects in this gene have been associated with congenital disorder of glycosylation type Ih (CDG-Ii). Alternative splicing results in multiple transcript variants. [provided by RefSeq, Nov 2008]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Pathogenic. Variant got 14 ACMG points.
PVS1
Loss of function variant, product does not undergo nonsense mediated mRNA decay. Variant is located in the 3'-most exon, not predicted to undergo nonsense mediated mRNA decay. Fraction of 0.169 CDS is truncated, and there are 0 pathogenic variants in the truncated region.
PM2
Very rare variant in population databases, with high coverage;
PP5
Variant 9-99218144-AC-A is Pathogenic according to our data. Variant chr9-99218144-AC-A is described in ClinVar as [Likely_pathogenic]. Clinvar id is 2699.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
ALG2 | NM_033087.4 | c.1040delG | p.Gly347fs | frameshift_variant | 2/2 | ENST00000476832.2 | NP_149078.1 | |
ALG2 | XM_047423996.1 | c.761delG | p.Gly254fs | frameshift_variant | 2/2 | XP_047279952.1 | ||
ALG2 | NR_024532.2 | n.1247delG | non_coding_transcript_exon_variant | 3/3 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
ALG2 | ENST00000476832.2 | c.1040delG | p.Gly347fs | frameshift_variant | 2/2 | 1 | NM_033087.4 | ENSP00000417764.1 | ||
ALG2 | ENST00000319033.7 | c.761delG | p.Gly254fs | frameshift_variant | 2/2 | 1 | ENSP00000326609.6 | |||
ALG2 | ENST00000238477.5 | n.*782delG | non_coding_transcript_exon_variant | 3/3 | 2 | ENSP00000432675.2 | ||||
ALG2 | ENST00000238477.5 | n.*782delG | 3_prime_UTR_variant | 3/3 | 2 | ENSP00000432675.2 |
Frequencies
GnomAD3 genomes AF: 0.0000723 AC: 11AN: 152196Hom.: 0 Cov.: 33
GnomAD3 genomes
AF:
AC:
11
AN:
152196
Hom.:
Cov.:
33
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.0000439 AC: 11AN: 250348Hom.: 0 AF XY: 0.0000444 AC XY: 6AN XY: 135286
GnomAD3 exomes
AF:
AC:
11
AN:
250348
Hom.:
AF XY:
AC XY:
6
AN XY:
135286
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.0000535 AC: 78AN: 1459032Hom.: 0 Cov.: 31 AF XY: 0.0000483 AC XY: 35AN XY: 725338
GnomAD4 exome
AF:
AC:
78
AN:
1459032
Hom.:
Cov.:
31
AF XY:
AC XY:
35
AN XY:
725338
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.0000723 AC: 11AN: 152196Hom.: 0 Cov.: 33 AF XY: 0.0000403 AC XY: 3AN XY: 74376
GnomAD4 genome
AF:
AC:
11
AN:
152196
Hom.:
Cov.:
33
AF XY:
AC XY:
3
AN XY:
74376
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Alfa
AF:
Hom.:
Bravo
AF:
EpiCase
AF:
EpiControl
AF:
ClinVar
Significance: Pathogenic/Likely pathogenic
Submissions summary: Pathogenic:4
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
ALG2-congenital disorder of glycosylation Pathogenic:2
Pathogenic, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Jun 10, 2024 | Variant summary: ALG2 c.1040delG (p.Gly347ValfsX27) results in a premature termination codon, predicted to cause a truncation of the encoded protein. The variant allele was found at a frequency of 4.4e-05 in 250348 control chromosomes (gnomAD). This frequency is not significantly higher than estimated for a pathogenic variant in ALG2 causing Congenital Disorder Of Glycosylation, Type 1i, allowing no conclusion about variant significance. c.1040delG has been reported in the literature in individuals affected with features of Congenital Disorder Of Glycosylation, Type 1i (Thiel_2003, Ehrstedt_2022). These publications report experimental evidence evaluating an impact on protein function, indicating that the variant results in a null allele. The following publications have been ascertained in the context of this evaluation (PMID: 12684507, 34980536). ClinVar contains an entry for this variant (Variation ID: 2699). Based on the evidence outlined above, the variant was classified as pathogenic. - |
Pathogenic, no assertion criteria provided | literature only | OMIM | Jun 20, 2003 | - - |
ALG2-congenital disorder of glycosylation;C4015597:Congenital myasthenic syndrome 14 Pathogenic:1
Likely pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jun 20, 2022 | ClinVar contains an entry for this variant (Variation ID: 2699). In summary, the currently available evidence indicates that the variant is pathogenic, but additional data are needed to prove that conclusively. Therefore, this variant has been classified as Likely Pathogenic. Experimental studies have shown that this premature translational stop signal affects ALG2 function (PMID: 12684507). Algorithms developed to predict the effect of variants on protein structure and function are not available or were not evaluated for this variant. This premature translational stop signal has been observed in individuals with ALG2-related disease (PMID: 12684507; Invitae). This variant is present in population databases (rs387906281, gnomAD 0.01%). This sequence change creates a premature translational stop signal (p.Gly347Valfs*27) in the ALG2 gene. While this is not anticipated to result in nonsense mediated decay, it is expected to disrupt the last 70 amino acid(s) of the ALG2 protein. - |
not provided Pathogenic:1
Likely pathogenic, criteria provided, single submitter | clinical testing | GeneDx | Sep 20, 2023 | Published functional studies demonstrate a damaging effect, as the variant is a null allele that results in significantly reduced expression (Ehrstedt et al., 2022); Frameshift variant predicted to result in protein truncation as the last 70 amino acids are replaced with 26 different amino acids, although loss-of-function variants have not been reported downstream of this position in the protein; This variant is associated with the following publications: (PMID: 12684507, 34980536) - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at